| Literature DB >> 26553423 |
Kang-shuai Li1,2, Peng Xiao1,3, Dao-lai Zhang1,4, Xu-Ben Hou3, Lin Ge1, Du-xiao Yang1, Hong-da Liu1, Dong-fang He1, Xu Chen2, Ke-rui Han5, Xiao-yuan Song6, Xiao Yu2, Hao Fang1, Jin-peng Sun7.
Abstract
Slingshot proteins form a small group of dual-specific phosphatases that modulate cytoskeleton dynamics through dephosphorylation of cofilin and Lim kinases (LIMK). Small chemical compounds with Slingshot-inhibiting activities have therapeutic potential against cancers or infectious diseases. However, only a few Slingshot inhibitors have been investigated and reported, and their cellular activities have not been examined. In this study, we identified two rhodanine-scaffold-based para-substituted benzoic acid derivatives as competitive Slingshot inhibitors. The top compound, (Z)-4-((4-((4-oxo-2-thioxo-3-(o-tolyl)thiazolidin-5-ylidene)methyl)phenoxy)methyl)benzoic acid (D3) had an inhibition constant (Ki) of around 4 μm and displayed selectivity over a panel of other phosphatases. Moreover, compound D3 inhibited cell migration and cofilin dephosphorylation after nerve growth factor (NGF) or angiotensin II stimulation. Therefore, our newly identified Slingshot inhibitors provide a starting point for developing Slingshot-targeted therapies.Entities:
Keywords: Slingshot; anticancer; cell migration; nerve growth factor (NGF); phosphatase inhibitors
Mesh:
Substances:
Year: 2015 PMID: 26553423 DOI: 10.1002/cmdc.201500454
Source DB: PubMed Journal: ChemMedChem ISSN: 1860-7179 Impact factor: 3.466